Drug intelligence / Profile preview

1-biphenyl-2-ylmethanamine

Development stage: Unknown
Modality: Small Molecules

Overview

1-biphenyl-2-ylmethanamine is a synthetic small molecule belonging to the biphenyl class of organic compounds. It has been studied as an experimental compound and is not approved for clinical use in any country. The compound acts as an inhibitor of dipeptidyl peptidase 4 (DPP4), a serine protease involved in glucose metabolism and immune regulation. There are no known approved indications or marketed products containing this substance, and it has not advanced beyond preclinical or early experimental research stages[1][3][5].

Other names: (2-phenylphenyl)methanamine2-phenylbenzylamine[1,1'-biphenyl]-2-ylmethanamine1-Biphenyl-2-YlmethanamineCAS 1924-77-2CAS1924-77-2CAS-1924-77-2

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on 1-biphenyl-2-ylmethanamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1-biphenyl-2-ylmethanamine.

Explore the full profile